Canakinumab Reduces Acute Flares In Gout Patients: Novartis Pharma
Preliminary results of Canakinumab were presented at the annual European League Against Rheumatism (EULAR) meeting in Rome, Italy. In the six month Phase II study, Canakinumab has reduced
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.